Name | Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
---|
Hydatidiform Mole | 27 | 2024 | 255 | 6.070 |
Why?
|
Ovarian Neoplasms | 67 | 2024 | 4904 | 3.870 |
Why?
|
Uterine Neoplasms | 34 | 2024 | 1425 | 3.270 |
Why?
|
Neoplasms, Glandular and Epithelial | 15 | 2018 | 488 | 2.430 |
Why?
|
Peritoneal Neoplasms | 20 | 2024 | 706 | 2.360 |
Why?
|
Fallopian Tube Neoplasms | 19 | 2022 | 329 | 2.180 |
Why?
|
Vulvar Neoplasms | 11 | 2024 | 265 | 2.050 |
Why?
|
Hysterectomy | 13 | 2024 | 864 | 1.770 |
Why?
|
Endometrial Neoplasms | 25 | 2022 | 1378 | 1.760 |
Why?
|
Trophoblastic Tumor, Placental Site | 4 | 2024 | 21 | 1.750 |
Why?
|
Antineoplastic Combined Chemotherapy Protocols | 38 | 2024 | 11858 | 1.630 |
Why?
|
Chorionic Gonadotropin | 17 | 2024 | 457 | 1.610 |
Why?
|
Genital Neoplasms, Female | 11 | 2024 | 534 | 1.460 |
Why?
|
Gynecologic Surgical Procedures | 8 | 2018 | 287 | 1.380 |
Why?
|
Carcinoma, Endometrioid | 10 | 2019 | 274 | 1.240 |
Why?
|
Pregnancy | 78 | 2024 | 30230 | 1.230 |
Why?
|
Choriocarcinoma | 5 | 2022 | 121 | 1.180 |
Why?
|
Methotrexate | 17 | 2024 | 1719 | 1.160 |
Why?
|
Neoplasm Recurrence, Local | 35 | 2023 | 9373 | 1.100 |
Why?
|
Cystadenocarcinoma, Serous | 10 | 2022 | 480 | 0.980 |
Why?
|
Dactinomycin | 12 | 2024 | 304 | 0.920 |
Why?
|
Neoplasm Staging | 53 | 2021 | 11196 | 0.880 |
Why?
|
Carcinoma, Squamous Cell | 11 | 2024 | 4044 | 0.800 |
Why?
|
Neoadjuvant Therapy | 12 | 2024 | 2895 | 0.770 |
Why?
|
Deoxycytidine | 3 | 2024 | 886 | 0.770 |
Why?
|
Adenocarcinoma, Clear Cell | 7 | 2015 | 217 | 0.760 |
Why?
|
Female | 208 | 2024 | 396141 | 0.760 |
Why?
|
CA-125 Antigen | 7 | 2017 | 282 | 0.710 |
Why?
|
Cisplatin | 5 | 2024 | 1654 | 0.680 |
Why?
|
Neoplasms, Cystic, Mucinous, and Serous | 6 | 2019 | 194 | 0.670 |
Why?
|
Neoplasm, Residual | 9 | 2021 | 1009 | 0.630 |
Why?
|
Radiotherapy, Intensity-Modulated | 2 | 2024 | 781 | 0.600 |
Why?
|
Disease-Free Survival | 27 | 2021 | 6838 | 0.600 |
Why?
|
Carcinoma in Situ | 7 | 2022 | 777 | 0.580 |
Why?
|
Granulosa Cell Tumor | 3 | 2019 | 76 | 0.560 |
Why?
|
Pregnancy Complications, Neoplastic | 3 | 2017 | 258 | 0.550 |
Why?
|
Lymph Node Excision | 5 | 2019 | 1258 | 0.540 |
Why?
|
Humans | 209 | 2024 | 765926 | 0.520 |
Why?
|
Antineoplastic Agents | 13 | 2021 | 13631 | 0.520 |
Why?
|
Quinazolines | 4 | 2022 | 1366 | 0.510 |
Why?
|
Organoplatinum Compounds | 4 | 2013 | 405 | 0.500 |
Why?
|
Remote Consultation | 1 | 2018 | 241 | 0.490 |
Why?
|
Vacuum Curettage | 3 | 2021 | 44 | 0.480 |
Why?
|
Brazil | 13 | 2023 | 1248 | 0.440 |
Why?
|
Middle Aged | 102 | 2024 | 223016 | 0.420 |
Why?
|
Uterine Cervical Neoplasms | 8 | 2021 | 2040 | 0.410 |
Why?
|
Retrospective Studies | 68 | 2024 | 81537 | 0.400 |
Why?
|
Drug Resistance, Neoplasm | 13 | 2023 | 5333 | 0.390 |
Why?
|
Chemotherapy, Adjuvant | 17 | 2024 | 3542 | 0.380 |
Why?
|
Adnexal Diseases | 2 | 2011 | 104 | 0.370 |
Why?
|
Adult | 85 | 2024 | 223088 | 0.360 |
Why?
|
Maternal Age | 4 | 2019 | 804 | 0.350 |
Why?
|
Carboplatin | 11 | 2022 | 787 | 0.340 |
Why?
|
Pelvic Neoplasms | 1 | 2011 | 248 | 0.330 |
Why?
|
Prognosis | 25 | 2024 | 29890 | 0.320 |
Why?
|
Aged | 72 | 2024 | 171163 | 0.320 |
Why?
|
Angiogenesis Inhibitors | 4 | 2013 | 2046 | 0.310 |
Why?
|
Etoposide | 6 | 2024 | 636 | 0.310 |
Why?
|
Carcinosarcoma | 3 | 2015 | 106 | 0.300 |
Why?
|
Retroperitoneal Neoplasms | 1 | 2011 | 335 | 0.300 |
Why?
|
Topotecan | 2 | 2006 | 130 | 0.290 |
Why?
|
Obesity | 5 | 2020 | 13082 | 0.290 |
Why?
|
Disease Management | 4 | 2024 | 2530 | 0.270 |
Why?
|
Risk Factors | 26 | 2024 | 74850 | 0.260 |
Why?
|
Aged, 80 and over | 35 | 2021 | 59496 | 0.260 |
Why?
|
Treatment Outcome | 31 | 2022 | 65194 | 0.250 |
Why?
|
Needs Assessment | 1 | 2012 | 1140 | 0.250 |
Why?
|
Cyclin-Dependent Kinase Inhibitor p16 | 2 | 2021 | 702 | 0.250 |
Why?
|
Bile Acids and Salts | 1 | 2007 | 398 | 0.240 |
Why?
|
Genes, BRCA1 | 4 | 2021 | 753 | 0.240 |
Why?
|
Antimetabolites, Antineoplastic | 3 | 2020 | 645 | 0.240 |
Why?
|
Leucovorin | 5 | 2021 | 643 | 0.230 |
Why?
|
Feasibility Studies | 6 | 2024 | 5300 | 0.230 |
Why?
|
Venous Thromboembolism | 3 | 2019 | 1883 | 0.230 |
Why?
|
Radiotherapy, Adjuvant | 8 | 2019 | 1777 | 0.230 |
Why?
|
Telemedicine | 5 | 2024 | 3108 | 0.220 |
Why?
|
Protein Kinase Inhibitors | 3 | 2012 | 5691 | 0.220 |
Why?
|
Cohort Studies | 22 | 2023 | 41680 | 0.220 |
Why?
|
Class I Phosphatidylinositol 3-Kinases | 2 | 2019 | 904 | 0.220 |
Why?
|
Patient Readmission | 3 | 2020 | 3282 | 0.220 |
Why?
|
Drug Administration Schedule | 10 | 2021 | 4851 | 0.220 |
Why?
|
Suction | 2 | 2020 | 268 | 0.220 |
Why?
|
Risk | 7 | 2022 | 9599 | 0.210 |
Why?
|
Carcinoma | 3 | 2022 | 2311 | 0.210 |
Why?
|
Models, Statistical | 1 | 2017 | 5088 | 0.210 |
Why?
|
Carcinoma, Papillary | 3 | 2014 | 786 | 0.200 |
Why?
|
Pneumatosis Cystoides Intestinalis | 1 | 2002 | 31 | 0.200 |
Why?
|
Myometrium | 2 | 2014 | 174 | 0.200 |
Why?
|
Hyperthyroidism | 2 | 2022 | 292 | 0.200 |
Why?
|
Sexual Behavior | 1 | 2012 | 2192 | 0.190 |
Why?
|
Blood Transfusion, Autologous | 1 | 2002 | 129 | 0.190 |
Why?
|
Carcinoma, Adenosquamous | 1 | 2002 | 66 | 0.190 |
Why?
|
Paclitaxel | 10 | 2022 | 1726 | 0.190 |
Why?
|
Laparoscopy | 4 | 2024 | 2037 | 0.190 |
Why?
|
Endometrial Hyperplasia | 1 | 2002 | 101 | 0.190 |
Why?
|
Genes, BRCA2 | 2 | 2015 | 591 | 0.190 |
Why?
|
Lymph Nodes | 4 | 2016 | 3447 | 0.190 |
Why?
|
Young Adult | 25 | 2024 | 59857 | 0.190 |
Why?
|
Enzyme Inhibitors | 1 | 2012 | 3716 | 0.180 |
Why?
|
Cyclodextrins | 1 | 2021 | 62 | 0.180 |
Why?
|
DNA Repair | 2 | 2018 | 2048 | 0.180 |
Why?
|
Survivors | 1 | 2012 | 2373 | 0.180 |
Why?
|
Brachytherapy | 2 | 2014 | 1218 | 0.180 |
Why?
|
Gravidity | 2 | 2021 | 50 | 0.180 |
Why?
|
Genital Diseases, Female | 1 | 2002 | 192 | 0.180 |
Why?
|
Uterine Artery | 1 | 2020 | 29 | 0.180 |
Why?
|
Doxorubicin | 3 | 2020 | 2226 | 0.180 |
Why?
|
Growth Differentiation Factor 2 | 1 | 2020 | 27 | 0.180 |
Why?
|
Kaplan-Meier Estimate | 9 | 2019 | 6503 | 0.170 |
Why?
|
Survival Rate | 12 | 2020 | 12822 | 0.170 |
Why?
|
Intestinal Perforation | 1 | 2002 | 254 | 0.170 |
Why?
|
Microsatellite Repeats | 1 | 2002 | 784 | 0.170 |
Why?
|
Blood Donors | 1 | 2002 | 344 | 0.170 |
Why?
|
Ultrasonic Therapy | 1 | 2001 | 216 | 0.170 |
Why?
|
Parity | 2 | 2016 | 931 | 0.170 |
Why?
|
Iodide Peroxidase | 1 | 2021 | 295 | 0.160 |
Why?
|
Fallopian Tubes | 2 | 2018 | 179 | 0.160 |
Why?
|
Ostomy | 1 | 2019 | 34 | 0.160 |
Why?
|
Uterine Hemorrhage | 3 | 2017 | 235 | 0.160 |
Why?
|
Cyclin-Dependent Kinase 6 | 1 | 2022 | 352 | 0.160 |
Why?
|
DNA Polymerase II | 1 | 2019 | 103 | 0.150 |
Why?
|
New England | 6 | 2017 | 1059 | 0.150 |
Why?
|
Pyrimidinones | 1 | 2021 | 384 | 0.150 |
Why?
|
Alphapapillomavirus | 1 | 2021 | 219 | 0.150 |
Why?
|
Precancerous Conditions | 3 | 2018 | 975 | 0.150 |
Why?
|
Paget Disease, Extramammary | 1 | 2018 | 50 | 0.140 |
Why?
|
Camptothecin | 1 | 2021 | 598 | 0.140 |
Why?
|
Mixed Tumor, Mullerian | 2 | 2008 | 55 | 0.140 |
Why?
|
Cervix Uteri | 1 | 2021 | 575 | 0.140 |
Why?
|
Heterocyclic Compounds, 3-Ring | 1 | 2019 | 295 | 0.140 |
Why?
|
Nomograms | 1 | 2019 | 235 | 0.140 |
Why?
|
Fluorodeoxyglucose F18 | 2 | 2008 | 2027 | 0.140 |
Why?
|
Hypothyroidism | 1 | 2022 | 665 | 0.140 |
Why?
|
Cyclophosphamide | 3 | 2023 | 2232 | 0.130 |
Why?
|
Gene Expression Regulation, Enzymologic | 1 | 2021 | 1167 | 0.130 |
Why?
|
Cysts | 1 | 2022 | 684 | 0.130 |
Why?
|
Demography | 2 | 2020 | 1640 | 0.130 |
Why?
|
Insurance Coverage | 2 | 2018 | 1945 | 0.130 |
Why?
|
Adenocarcinoma | 4 | 2019 | 6360 | 0.130 |
Why?
|
Disease Progression | 4 | 2021 | 13614 | 0.130 |
Why?
|
Neoplasms, Multiple Primary | 2 | 2017 | 589 | 0.130 |
Why?
|
Drug Substitution | 1 | 2019 | 292 | 0.130 |
Why?
|
Endometrium | 1 | 2019 | 404 | 0.130 |
Why?
|
Adenocarcinoma, Mucinous | 3 | 2014 | 521 | 0.130 |
Why?
|
Evidence-Based Medicine | 2 | 2021 | 3690 | 0.130 |
Why?
|
Pilot Projects | 6 | 2024 | 8724 | 0.130 |
Why?
|
Cross-Sectional Studies | 7 | 2023 | 26282 | 0.130 |
Why?
|
Radiopharmaceuticals | 2 | 2008 | 2701 | 0.130 |
Why?
|
Bismuth | 1 | 1995 | 28 | 0.130 |
Why?
|
Early Detection of Cancer | 3 | 2021 | 3238 | 0.130 |
Why?
|
Pelvis | 2 | 2014 | 737 | 0.130 |
Why?
|
Immunohistochemistry | 7 | 2019 | 11030 | 0.120 |
Why?
|
Antitoxins | 1 | 1995 | 75 | 0.120 |
Why?
|
Omentum | 3 | 2019 | 167 | 0.120 |
Why?
|
Regression Analysis | 2 | 2017 | 6321 | 0.120 |
Why?
|
Tissue Banks | 1 | 2016 | 183 | 0.120 |
Why?
|
Trophoblastic Neoplasms | 1 | 2015 | 89 | 0.120 |
Why?
|
Length of Stay | 3 | 2020 | 6486 | 0.120 |
Why?
|
Multivariate Analysis | 5 | 2020 | 12059 | 0.120 |
Why?
|
Caregivers | 2 | 2024 | 2304 | 0.120 |
Why?
|
Maximum Tolerated Dose | 2 | 2015 | 895 | 0.120 |
Why?
|
Lymphatic Metastasis | 7 | 2014 | 2885 | 0.120 |
Why?
|
Colposcopy | 3 | 2021 | 151 | 0.120 |
Why?
|
Receptors, Estrogen | 2 | 2022 | 2242 | 0.120 |
Why?
|
Cystadenocarcinoma, Papillary | 2 | 2006 | 56 | 0.120 |
Why?
|
Neoplastic Syndromes, Hereditary | 1 | 2017 | 249 | 0.110 |
Why?
|
Adrenergic beta-Antagonists | 1 | 2020 | 1238 | 0.110 |
Why?
|
Receptors, Progesterone | 1 | 2019 | 1152 | 0.110 |
Why?
|
Medroxyprogesterone Acetate | 1 | 2014 | 153 | 0.110 |
Why?
|
Proto-Oncogene Proteins c-bcl-2 | 1 | 2020 | 1407 | 0.110 |
Why?
|
Diagnosis, Differential | 7 | 2019 | 12973 | 0.110 |
Why?
|
Radiation Injuries | 2 | 2014 | 1181 | 0.110 |
Why?
|
Erythrocyte Transfusion | 1 | 2019 | 574 | 0.110 |
Why?
|
Sarcoma, Endometrial Stromal | 1 | 2014 | 92 | 0.110 |
Why?
|
Colectomy | 1 | 2019 | 697 | 0.110 |
Why?
|
Watchful Waiting | 1 | 2017 | 492 | 0.110 |
Why?
|
Apoptosis | 2 | 2020 | 9505 | 0.110 |
Why?
|
Antibiotics, Antineoplastic | 2 | 2020 | 678 | 0.110 |
Why?
|
BRCA1 Protein | 2 | 2022 | 1155 | 0.110 |
Why?
|
Pyrazoles | 2 | 2021 | 2031 | 0.110 |
Why?
|
Cholera Toxin | 1 | 1995 | 562 | 0.110 |
Why?
|
Pregnancy Outcome | 2 | 2021 | 2969 | 0.100 |
Why?
|
Vincristine | 3 | 2023 | 1037 | 0.100 |
Why?
|
Diagnostic Imaging | 3 | 2013 | 3530 | 0.100 |
Why?
|
Colorectal Neoplasms, Hereditary Nonpolyposis | 1 | 2017 | 388 | 0.100 |
Why?
|
Registries | 4 | 2024 | 8346 | 0.100 |
Why?
|
Case-Control Studies | 10 | 2014 | 22228 | 0.100 |
Why?
|
Papillomavirus Infections | 3 | 2021 | 1637 | 0.100 |
Why?
|
Hydroxamic Acids | 1 | 2015 | 483 | 0.100 |
Why?
|
Folate Receptors, GPI-Anchored | 1 | 2012 | 23 | 0.100 |
Why?
|
Survival Analysis | 7 | 2020 | 10086 | 0.100 |
Why?
|
Organoids | 1 | 2018 | 740 | 0.100 |
Why?
|
Immunity, Mucosal | 1 | 1995 | 498 | 0.100 |
Why?
|
Papillomaviridae | 2 | 2016 | 1137 | 0.100 |
Why?
|
Quality of Life | 4 | 2024 | 13463 | 0.100 |
Why?
|
Protein-Tyrosine Kinases | 1 | 2021 | 2423 | 0.100 |
Why?
|
Taxoids | 2 | 2012 | 665 | 0.090 |
Why?
|
Body Mass Index | 3 | 2016 | 13042 | 0.090 |
Why?
|
Infusions, Parenteral | 3 | 2021 | 395 | 0.090 |
Why?
|
Adolescent | 17 | 2021 | 88811 | 0.090 |
Why?
|
Prenatal Diagnosis | 1 | 2018 | 1271 | 0.090 |
Why?
|
Gene Expression Regulation, Neoplastic | 3 | 2020 | 8603 | 0.090 |
Why?
|
Practice Guidelines as Topic | 3 | 2021 | 7423 | 0.090 |
Why?
|
Cell Proliferation | 3 | 2020 | 10426 | 0.090 |
Why?
|
Abortion, Induced | 1 | 2017 | 471 | 0.090 |
Why?
|
Enzyme-Linked Immunosorbent Assay | 3 | 2021 | 3801 | 0.090 |
Why?
|
Follow-Up Studies | 8 | 2020 | 39228 | 0.090 |
Why?
|
Mutation | 7 | 2022 | 30192 | 0.090 |
Why?
|
Decision Making | 1 | 2024 | 3955 | 0.090 |
Why?
|
DNA Methylation | 2 | 2017 | 4424 | 0.090 |
Why?
|
Neoplasm Proteins | 1 | 2002 | 3592 | 0.090 |
Why?
|
Neoplasm Invasiveness | 6 | 2018 | 3599 | 0.090 |
Why?
|
BRCA2 Protein | 1 | 2015 | 802 | 0.080 |
Why?
|
Neutrophils | 1 | 2022 | 3769 | 0.080 |
Why?
|
Age Factors | 4 | 2019 | 18382 | 0.080 |
Why?
|
Pre-Eclampsia | 2 | 2017 | 1257 | 0.080 |
Why?
|
Brain Neoplasms | 2 | 2024 | 9065 | 0.080 |
Why?
|
Referral and Consultation | 3 | 2021 | 3615 | 0.080 |
Why?
|
Cell Cycle Proteins | 1 | 2021 | 3431 | 0.080 |
Why?
|
Cell Death | 1 | 2015 | 1676 | 0.080 |
Why?
|
Gravitation | 1 | 2009 | 82 | 0.080 |
Why?
|
Cell Lineage | 1 | 2018 | 2573 | 0.080 |
Why?
|
Surgical Wound Infection | 1 | 2019 | 1544 | 0.080 |
Why?
|
Phthalazines | 2 | 2022 | 397 | 0.080 |
Why?
|
Palliative Care | 1 | 2024 | 3640 | 0.080 |
Why?
|
Patient Acceptance of Health Care | 2 | 2024 | 3230 | 0.080 |
Why?
|
Anesthetics | 1 | 2014 | 525 | 0.080 |
Why?
|
Infusions, Intravenous | 4 | 2020 | 2227 | 0.080 |
Why?
|
Insurance, Health | 2 | 2018 | 2520 | 0.080 |
Why?
|
Nursing Homes | 1 | 2016 | 1084 | 0.080 |
Why?
|
Germ-Line Mutation | 2 | 2015 | 1885 | 0.080 |
Why?
|
Stomach Neoplasms | 1 | 2019 | 1469 | 0.080 |
Why?
|
Radiology | 2 | 2013 | 2105 | 0.080 |
Why?
|
South America | 2 | 2020 | 180 | 0.080 |
Why?
|
Time Factors | 8 | 2020 | 40097 | 0.080 |
Why?
|
Cell Transformation, Neoplastic | 1 | 2018 | 2838 | 0.070 |
Why?
|
Folic Acid | 1 | 2015 | 1337 | 0.070 |
Why?
|
Cholic Acid | 1 | 2007 | 30 | 0.070 |
Why?
|
Remission Induction | 3 | 2020 | 2413 | 0.070 |
Why?
|
Polyethylene Glycols | 2 | 2020 | 1189 | 0.070 |
Why?
|
Tetrazolium Salts | 1 | 2007 | 92 | 0.070 |
Why?
|
Genes, erbB-1 | 1 | 2008 | 161 | 0.070 |
Why?
|
Membrane Proteins | 2 | 2017 | 7847 | 0.070 |
Why?
|
Chenodeoxycholic Acid | 1 | 2007 | 34 | 0.070 |
Why?
|
Deoxycholic Acid | 1 | 2007 | 54 | 0.070 |
Why?
|
Ursodeoxycholic Acid | 1 | 2007 | 81 | 0.070 |
Why?
|
Hedgehog Proteins | 1 | 2012 | 772 | 0.070 |
Why?
|
Abdomen | 1 | 2013 | 1135 | 0.070 |
Why?
|
Vulva | 1 | 2007 | 84 | 0.070 |
Why?
|
Intensive Care Units | 2 | 2017 | 3799 | 0.070 |
Why?
|
Contraceptives, Oral | 1 | 2009 | 559 | 0.070 |
Why?
|
Exercise | 2 | 2021 | 5936 | 0.070 |
Why?
|
Ovariectomy | 2 | 2022 | 612 | 0.070 |
Why?
|
Epithelial Cells | 1 | 2018 | 3684 | 0.070 |
Why?
|
Breast Neoplasms | 4 | 2022 | 21069 | 0.070 |
Why?
|
Costs and Cost Analysis | 1 | 2012 | 1666 | 0.070 |
Why?
|
United States | 11 | 2021 | 72909 | 0.070 |
Why?
|
Antineoplastic Agents, Hormonal | 1 | 2014 | 1535 | 0.070 |
Why?
|
Tomography, Spiral Computed | 1 | 2008 | 273 | 0.070 |
Why?
|
Receptors, Vascular Endothelial Growth Factor | 1 | 2009 | 658 | 0.060 |
Why?
|
Postoperative Complications | 5 | 2020 | 15802 | 0.060 |
Why?
|
Pyrroles | 1 | 2012 | 1119 | 0.060 |
Why?
|
Research Design | 1 | 2022 | 6204 | 0.060 |
Why?
|
Intestinal Obstruction | 1 | 2010 | 433 | 0.060 |
Why?
|
Weight Loss | 1 | 2017 | 2710 | 0.060 |
Why?
|
Health Services Accessibility | 1 | 2023 | 5509 | 0.060 |
Why?
|
Endometriosis | 1 | 2014 | 869 | 0.060 |
Why?
|
Ligands | 2 | 2022 | 3272 | 0.060 |
Why?
|
Patient Discharge | 2 | 2016 | 3460 | 0.060 |
Why?
|
Predictive Value of Tests | 3 | 2017 | 15401 | 0.060 |
Why?
|
Pulmonary Embolism | 1 | 2019 | 2596 | 0.060 |
Why?
|
Coloring Agents | 1 | 2007 | 562 | 0.060 |
Why?
|
Combined Modality Therapy | 5 | 2012 | 8522 | 0.060 |
Why?
|
Genes, MDR | 1 | 2004 | 36 | 0.060 |
Why?
|
MicroRNAs | 1 | 2020 | 3788 | 0.060 |
Why?
|
Family Health | 1 | 2009 | 1253 | 0.060 |
Why?
|
Randomized Controlled Trials as Topic | 2 | 2021 | 10380 | 0.060 |
Why?
|
Abortion, Spontaneous | 2 | 2021 | 536 | 0.060 |
Why?
|
Carcinoma, Transitional Cell | 2 | 2013 | 789 | 0.060 |
Why?
|
Indoles | 1 | 2012 | 1833 | 0.060 |
Why?
|
Microvessels | 1 | 2008 | 590 | 0.060 |
Why?
|
Drug Costs | 1 | 2012 | 1194 | 0.060 |
Why?
|
Overweight | 1 | 2015 | 2444 | 0.050 |
Why?
|
Platinum Compounds | 2 | 2014 | 94 | 0.050 |
Why?
|
Nucleosomes | 1 | 2007 | 492 | 0.050 |
Why?
|
Uterine Cervical Dysplasia | 1 | 2007 | 391 | 0.050 |
Why?
|
Tumor Suppressor Protein p53 | 3 | 2018 | 2945 | 0.050 |
Why?
|
Cellular Structures | 1 | 2022 | 9 | 0.050 |
Why?
|
Preoperative Care | 1 | 2012 | 2248 | 0.050 |
Why?
|
Proto-Oncogene Proteins c-akt | 1 | 2012 | 2455 | 0.050 |
Why?
|
Protein Kinase C | 1 | 2007 | 1202 | 0.050 |
Why?
|
Ribose | 1 | 2022 | 63 | 0.050 |
Why?
|
Coronavirus Infections | 1 | 2020 | 3109 | 0.050 |
Why?
|
Base Pair Mismatch | 1 | 2002 | 93 | 0.050 |
Why?
|
Diphosphates | 1 | 2022 | 91 | 0.050 |
Why?
|
Pneumonia, Viral | 1 | 2020 | 3231 | 0.050 |
Why?
|
Laparotomy | 1 | 2024 | 459 | 0.050 |
Why?
|
Sperm Injections, Intracytoplasmic | 1 | 2023 | 156 | 0.050 |
Why?
|
Peritoneal Cavity | 1 | 2022 | 135 | 0.050 |
Why?
|
Proportional Hazards Models | 5 | 2018 | 12529 | 0.050 |
Why?
|
Fertilization | 1 | 2023 | 197 | 0.050 |
Why?
|
Drug Screening Assays, Antitumor | 1 | 2004 | 715 | 0.050 |
Why?
|
Administration, Intravaginal | 1 | 2002 | 149 | 0.050 |
Why?
|
Blood Cell Count | 1 | 2022 | 404 | 0.050 |
Why?
|
Medical Oncology | 1 | 2013 | 2339 | 0.050 |
Why?
|
Lutein | 1 | 2022 | 122 | 0.050 |
Why?
|
Antibodies, Monoclonal | 4 | 2022 | 9239 | 0.050 |
Why?
|
Vagina | 1 | 2007 | 849 | 0.050 |
Why?
|
High-Throughput Nucleotide Sequencing | 3 | 2020 | 3661 | 0.050 |
Why?
|
Pancreatic Neoplasms | 1 | 2019 | 5450 | 0.050 |
Why?
|
Lymphatic System | 1 | 2002 | 250 | 0.050 |
Why?
|
SEER Program | 2 | 2018 | 1443 | 0.040 |
Why?
|
Hysteroscopy | 1 | 2021 | 62 | 0.040 |
Why?
|
Biopsy | 2 | 2004 | 6766 | 0.040 |
Why?
|
Molecular Targeted Therapy | 1 | 2012 | 2823 | 0.040 |
Why?
|
Neoplasms | 2 | 2022 | 22340 | 0.040 |
Why?
|
Signal Transduction | 2 | 2015 | 23597 | 0.040 |
Why?
|
Mitoxantrone | 1 | 2020 | 148 | 0.040 |
Why?
|
Ascites | 2 | 2017 | 336 | 0.040 |
Why?
|
Prospective Studies | 6 | 2022 | 54807 | 0.040 |
Why?
|
Semen | 1 | 2023 | 351 | 0.040 |
Why?
|
Radiation Dosage | 2 | 2014 | 1945 | 0.040 |
Why?
|
Thiazoles | 1 | 2007 | 1528 | 0.040 |
Why?
|
Sensitivity and Specificity | 3 | 2021 | 14643 | 0.040 |
Why?
|
Self Efficacy | 1 | 2024 | 641 | 0.040 |
Why?
|
Positron-Emission Tomography | 2 | 2008 | 6542 | 0.040 |
Why?
|
X-Rays | 1 | 2021 | 309 | 0.040 |
Why?
|
Lung Neoplasms | 2 | 2021 | 13446 | 0.040 |
Why?
|
Electrocoagulation | 1 | 2020 | 157 | 0.040 |
Why?
|
Drug Interactions | 1 | 2004 | 1416 | 0.040 |
Why?
|
Community Health Centers | 1 | 2023 | 469 | 0.040 |
Why?
|
Guideline Adherence | 1 | 2010 | 2234 | 0.040 |
Why?
|
Selenoproteins | 1 | 2021 | 216 | 0.040 |
Why?
|
Adnexa Uteri | 1 | 2019 | 40 | 0.040 |
Why?
|
Abortion, Habitual | 1 | 2019 | 65 | 0.040 |
Why?
|
DNA Mismatch Repair | 1 | 2022 | 432 | 0.040 |
Why?
|
Fibrinolytic Agents | 1 | 2009 | 2076 | 0.040 |
Why?
|
Cell Line, Tumor | 2 | 2007 | 17060 | 0.040 |
Why?
|
Neoplasm Metastasis | 3 | 2016 | 4882 | 0.040 |
Why?
|
Pneumothorax | 1 | 2002 | 392 | 0.040 |
Why?
|
Societies, Medical | 1 | 2011 | 3953 | 0.040 |
Why?
|
HSP90 Heat-Shock Proteins | 1 | 2021 | 422 | 0.040 |
Why?
|
Sweden | 1 | 2002 | 1381 | 0.040 |
Why?
|
Models, Biological | 1 | 2015 | 9443 | 0.040 |
Why?
|
Thyrotropin | 1 | 2022 | 834 | 0.040 |
Why?
|
Online Systems | 1 | 2019 | 181 | 0.040 |
Why?
|
Stillbirth | 1 | 2021 | 381 | 0.040 |
Why?
|
Cyclin-Dependent Kinase 4 | 1 | 2022 | 561 | 0.040 |
Why?
|
Reoperation | 2 | 2020 | 4308 | 0.040 |
Why?
|
Cytarabine | 1 | 2020 | 696 | 0.040 |
Why?
|
Neovascularization, Pathologic | 1 | 2008 | 2627 | 0.040 |
Why?
|
Immunotherapy | 2 | 2024 | 4746 | 0.040 |
Why?
|
Placenta | 2 | 2022 | 1726 | 0.040 |
Why?
|
Pandemics | 3 | 2022 | 8721 | 0.040 |
Why?
|
Ultrasonography | 1 | 2010 | 5987 | 0.040 |
Why?
|
Vascular Endothelial Growth Factor A | 1 | 2008 | 3498 | 0.040 |
Why?
|
Mass Screening | 2 | 2010 | 5449 | 0.030 |
Why?
|
Vitamin A | 1 | 2020 | 611 | 0.030 |
Why?
|
Colorectal Neoplasms | 1 | 2017 | 6958 | 0.030 |
Why?
|
Aorta | 1 | 2004 | 2040 | 0.030 |
Why?
|
Boston | 3 | 2017 | 9334 | 0.030 |
Why?
|
Advance Care Planning | 1 | 2024 | 698 | 0.030 |
Why?
|
In Situ Hybridization, Fluorescence | 2 | 2016 | 2510 | 0.030 |
Why?
|
Gastrointestinal Neoplasms | 1 | 2024 | 958 | 0.030 |
Why?
|
Fat Necrosis | 1 | 1996 | 58 | 0.030 |
Why?
|
Medical Records | 1 | 2002 | 1408 | 0.030 |
Why?
|
Genes, p53 | 1 | 2018 | 711 | 0.030 |
Why?
|
Organ Culture Techniques | 1 | 2018 | 788 | 0.030 |
Why?
|
Gastrointestinal Agents | 1 | 2001 | 511 | 0.030 |
Why?
|
Sodium Salicylate | 1 | 1995 | 18 | 0.030 |
Why?
|
Retroperitoneal Space | 1 | 2016 | 175 | 0.030 |
Why?
|
Ovary | 1 | 2020 | 961 | 0.030 |
Why?
|
Pregnancy, Multiple | 1 | 2017 | 216 | 0.030 |
Why?
|
ROC Curve | 2 | 2017 | 3612 | 0.030 |
Why?
|
Drug Synergism | 1 | 2019 | 1751 | 0.030 |
Why?
|
Salicylates | 1 | 1995 | 125 | 0.030 |
Why?
|
Quality-Adjusted Life Years | 1 | 2002 | 1740 | 0.030 |
Why?
|
Chorionic Gonadotropin, beta Subunit, Human | 1 | 2015 | 83 | 0.030 |
Why?
|
Fetal Death | 1 | 2017 | 434 | 0.030 |
Why?
|
Neck | 1 | 1999 | 735 | 0.030 |
Why?
|
Administration, Oral | 2 | 2009 | 4016 | 0.030 |
Why?
|
HeLa Cells | 1 | 2021 | 3070 | 0.030 |
Why?
|
Sirolimus | 1 | 2022 | 1541 | 0.030 |
Why?
|
Lymphocytes | 1 | 2022 | 2601 | 0.030 |
Why?
|
Lymphocytes, Tumor-Infiltrating | 1 | 2020 | 1104 | 0.030 |
Why?
|
Genetic Markers | 1 | 2020 | 2603 | 0.030 |
Why?
|
Triage | 1 | 2021 | 994 | 0.030 |
Why?
|
Dose-Response Relationship, Drug | 2 | 2020 | 10727 | 0.030 |
Why?
|
DNA Mutational Analysis | 2 | 2015 | 4111 | 0.030 |
Why?
|
Equipment Design | 1 | 2001 | 3490 | 0.030 |
Why?
|
Live Birth | 1 | 2017 | 516 | 0.030 |
Why?
|
North America | 1 | 2017 | 1287 | 0.030 |
Why?
|
Phosphatidylinositol 3-Kinases | 1 | 2022 | 2877 | 0.030 |
Why?
|
Qualitative Research | 1 | 2024 | 3136 | 0.030 |
Why?
|
Tumor Cells, Cultured | 1 | 2020 | 6101 | 0.030 |
Why?
|
Massachusetts | 2 | 2018 | 8882 | 0.030 |
Why?
|
Observer Variation | 1 | 2019 | 2611 | 0.030 |
Why?
|
Immunoglobulin A | 2 | 1995 | 992 | 0.030 |
Why?
|
TOR Serine-Threonine Kinases | 1 | 2022 | 2057 | 0.030 |
Why?
|
North Carolina | 1 | 2013 | 329 | 0.030 |
Why?
|
Pyrazines | 1 | 2018 | 1204 | 0.030 |
Why?
|
Incidence | 3 | 2016 | 21513 | 0.030 |
Why?
|
Antioxidants | 1 | 2020 | 1671 | 0.020 |
Why?
|
Xenograft Model Antitumor Assays | 1 | 2020 | 3604 | 0.020 |
Why?
|
Sentinel Lymph Node Biopsy | 1 | 2016 | 730 | 0.020 |
Why?
|
Organometallic Compounds | 1 | 1995 | 645 | 0.020 |
Why?
|
Vitamins | 1 | 2020 | 1631 | 0.020 |
Why?
|
Gestational Age | 1 | 2021 | 3616 | 0.020 |
Why?
|
Receptor, erbB-2 | 1 | 2022 | 2592 | 0.020 |
Why?
|
Adaptor Proteins, Signal Transducing | 1 | 2002 | 2897 | 0.020 |
Why?
|
Tomography, X-Ray Computed | 4 | 2021 | 20690 | 0.020 |
Why?
|
Injections, Intraperitoneal | 1 | 2012 | 410 | 0.020 |
Why?
|
Magnetic Resonance Spectroscopy | 1 | 2021 | 3678 | 0.020 |
Why?
|
Splenectomy | 1 | 2013 | 389 | 0.020 |
Why?
|
Health Knowledge, Attitudes, Practice | 1 | 2006 | 4055 | 0.020 |
Why?
|
Gene Dosage | 1 | 2016 | 1213 | 0.020 |
Why?
|
Diaphragm | 1 | 2013 | 356 | 0.020 |
Why?
|
Killer Cells, Natural | 1 | 2020 | 2206 | 0.020 |
Why?
|
DNA Replication | 1 | 2018 | 1428 | 0.020 |
Why?
|
Gene Expression Profiling | 1 | 2007 | 9525 | 0.020 |
Why?
|
Immunization | 1 | 1995 | 1218 | 0.020 |
Why?
|
Radiography | 1 | 2002 | 6941 | 0.020 |
Why?
|
Histocytochemistry | 1 | 2012 | 695 | 0.020 |
Why?
|
Motivation | 1 | 2021 | 2018 | 0.020 |
Why?
|
Perioperative Care | 1 | 2019 | 1042 | 0.020 |
Why?
|
Promoter Regions, Genetic | 1 | 2002 | 5784 | 0.020 |
Why?
|
Postoperative Period | 1 | 2015 | 1818 | 0.020 |
Why?
|
Intestine, Large | 1 | 2010 | 69 | 0.020 |
Why?
|
Leukemia, Myelogenous, Chronic, BCR-ABL Positive | 1 | 2015 | 685 | 0.020 |
Why?
|
World Health Organization | 1 | 2016 | 1326 | 0.020 |
Why?
|
Intestines | 1 | 2019 | 1906 | 0.020 |
Why?
|
Genetic Predisposition to Disease | 3 | 2018 | 18074 | 0.020 |
Why?
|
Tumor Necrosis Factor-alpha | 1 | 2001 | 4342 | 0.020 |
Why?
|
Risk Assessment | 2 | 2009 | 24275 | 0.020 |
Why?
|
Hepatectomy | 1 | 2013 | 588 | 0.020 |
Why?
|
Clinical Competence | 1 | 2005 | 4855 | 0.020 |
Why?
|
Immunoglobulin E | 1 | 1995 | 1479 | 0.020 |
Why?
|
DNA, Viral | 1 | 2016 | 2196 | 0.020 |
Why?
|
Blood Transfusion | 1 | 2016 | 1307 | 0.020 |
Why?
|
RNA, Messenger | 1 | 2004 | 12768 | 0.020 |
Why?
|
Carrier Proteins | 1 | 2002 | 4909 | 0.020 |
Why?
|
Oxidative Stress | 1 | 2020 | 3140 | 0.020 |
Why?
|
Cost-Benefit Analysis | 1 | 2002 | 5531 | 0.020 |
Why?
|
Feces | 1 | 1995 | 1503 | 0.020 |
Why?
|
Phenotype | 2 | 2018 | 16714 | 0.020 |
Why?
|
Pregnancy Complications | 1 | 2002 | 2970 | 0.020 |
Why?
|
Pancreatectomy | 1 | 2013 | 824 | 0.020 |
Why?
|
Robotics | 1 | 2015 | 807 | 0.020 |
Why?
|
Mice | 3 | 2022 | 81782 | 0.020 |
Why?
|
Crohn Disease | 1 | 2001 | 2281 | 0.020 |
Why?
|
Proteomics | 1 | 2022 | 3906 | 0.020 |
Why?
|
Tumor Burden | 1 | 2014 | 1888 | 0.020 |
Why?
|
Child | 4 | 2019 | 80568 | 0.020 |
Why?
|
Calcinosis | 1 | 1996 | 1475 | 0.020 |
Why?
|
Nuclear Proteins | 1 | 2002 | 5782 | 0.020 |
Why?
|
Guanine | 1 | 2008 | 281 | 0.020 |
Why?
|
Iopamidol | 1 | 2008 | 188 | 0.020 |
Why?
|
Glutamates | 1 | 2008 | 384 | 0.020 |
Why?
|
Microdissection | 1 | 2007 | 150 | 0.020 |
Why?
|
Angiopoietin-2 | 1 | 2008 | 186 | 0.020 |
Why?
|
CD8-Positive T-Lymphocytes | 1 | 2020 | 4641 | 0.020 |
Why?
|
Vaginal Neoplasms | 1 | 2007 | 105 | 0.020 |
Why?
|
Genomics | 1 | 2022 | 5925 | 0.020 |
Why?
|
Life Style | 1 | 2017 | 3928 | 0.020 |
Why?
|
Gastrointestinal Diseases | 1 | 2014 | 1204 | 0.020 |
Why?
|
Genotype | 1 | 2019 | 13026 | 0.020 |
Why?
|
Critical Care | 1 | 2017 | 2713 | 0.010 |
Why?
|
RNA, Neoplasm | 1 | 2007 | 745 | 0.010 |
Why?
|
Immunoglobulin G | 2 | 1995 | 4555 | 0.010 |
Why?
|
Premature Birth | 1 | 2017 | 1830 | 0.010 |
Why?
|
Odds Ratio | 1 | 2016 | 9656 | 0.010 |
Why?
|
Gene Amplification | 1 | 2008 | 1088 | 0.010 |
Why?
|
Intestine, Small | 1 | 2010 | 1216 | 0.010 |
Why?
|
Animals | 3 | 2022 | 168735 | 0.010 |
Why?
|
Logistic Models | 1 | 2018 | 13273 | 0.010 |
Why?
|
Lasers | 1 | 2007 | 951 | 0.010 |
Why?
|
Necrosis | 1 | 2007 | 1611 | 0.010 |
Why?
|
Epithelium | 1 | 2007 | 1603 | 0.010 |
Why?
|
Infant, Newborn | 1 | 2022 | 26380 | 0.010 |
Why?
|
Healthcare Disparities | 1 | 2018 | 3407 | 0.010 |
Why?
|
Genetic Testing | 1 | 2015 | 3594 | 0.010 |
Why?
|
Stromal Cells | 1 | 2007 | 1332 | 0.010 |
Why?
|
Mitochondria | 1 | 2015 | 3669 | 0.010 |
Why?
|
Primary Prevention | 1 | 2009 | 1187 | 0.010 |
Why?
|
Transcriptional Activation | 1 | 2007 | 1743 | 0.010 |
Why?
|
Cell Line | 1 | 2015 | 15540 | 0.010 |
Why?
|
Infant | 1 | 2023 | 36426 | 0.010 |
Why?
|
Radiotherapy | 1 | 2007 | 1491 | 0.010 |
Why?
|
Reverse Transcriptase Polymerase Chain Reaction | 1 | 2007 | 4563 | 0.010 |
Why?
|
Prevalence | 1 | 2017 | 15828 | 0.010 |
Why?
|
Pregnancy Trimester, Third | 1 | 2002 | 587 | 0.010 |
Why?
|
Vaginal Smears | 1 | 2002 | 506 | 0.010 |
Why?
|
Oligonucleotide Array Sequence Analysis | 1 | 2007 | 3796 | 0.010 |
Why?
|
Vascular Surgical Procedures | 1 | 2007 | 1506 | 0.010 |
Why?
|
Liver Neoplasms | 1 | 2013 | 4349 | 0.010 |
Why?
|
Mice, Inbred C57BL | 1 | 1995 | 22327 | 0.010 |
Why?
|
Cell Differentiation | 1 | 2014 | 11639 | 0.010 |
Why?
|
Safety | 1 | 2001 | 1157 | 0.010 |
Why?
|
Carcinoma, Non-Small-Cell Lung | 1 | 2015 | 5379 | 0.010 |
Why?
|
Smoking | 2 | 2007 | 9082 | 0.010 |
Why?
|
Pneumonectomy | 1 | 2002 | 1128 | 0.010 |
Why?
|
Contrast Media | 1 | 2008 | 5330 | 0.010 |
Why?
|
Comorbidity | 1 | 2009 | 10575 | 0.010 |
Why?
|
Magnetic Resonance Imaging | 1 | 2021 | 36547 | 0.010 |
Why?
|
Axilla | 1 | 1996 | 615 | 0.010 |
Why?
|
Postmenopause | 1 | 2002 | 2517 | 0.010 |
Why?
|
Simplexvirus | 1 | 1976 | 804 | 0.010 |
Why?
|
Immunity | 1 | 1976 | 1000 | 0.010 |
Why?
|
Male | 3 | 2023 | 363815 | 0.000 |
Why?
|
Mammography | 1 | 1996 | 2424 | 0.000 |
Why?
|
Antibodies, Viral | 1 | 1976 | 3213 | 0.000 |
Why?
|
Antibody Formation | 1 | 1976 | 1392 | 0.000 |
Why?
|
Immunoglobulin M | 1 | 1976 | 1527 | 0.000 |
Why?
|
Alcohol Drinking | 1 | 1976 | 4041 | 0.000 |
Why?
|